Compare
Side by side.
| Dasatinib + Quercetin | Metformin | |
|---|---|---|
| Evidence | GRADE D | GRADE B |
| Category | senolytic | metabolic |
| Status | Rx | Rx |
| Typical cost | $100–$400 / course | $5–$20 / mo |
| Mechanism | Senescent cells accumulate with age and secrete inflammatory signals. D+Q triggers their self-destruction, reducing that inflammatory burden. | Lowers glucose production by the liver and improves insulin sensitivity. It mildly affects mitochondrial energy signaling (AMPK), which may mimic some effects of caloric restriction. |
| Human evidence | Extended healthspan in aged mice. Small human pilot studies in idiopathic pulmonary fibrosis and diabetic kidney disease showed reduced senescent markers and some function signals. Safety in healthy people is unestablished. | Observational data suggest diabetics on metformin may have outcomes comparable to non-diabetics. The TAME trial is designed to test aging outcomes but has not reported. Some data suggest it can blunt exercise adaptations in older adults. |
| Side effects | Dasatinib: low blood counts, fluid retention, GI effects · Quercetin: generally mild | GI upset, diarrhea · Vitamin B12 deficiency with long use · Rare lactic acidosis (kidney impairment) |
Not medical advice — talk to a licensed clinician. Content is educational, reflects published literature, and is not a recommendation to start, stop or change any treatment.